Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study
Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non–Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised...
Saved in:
| Published in | Blood Vol. 126; no. 13; pp. 1575 - 1584 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
24.09.2015
American Society of Hematology |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0006-4971 1528-0020 1528-0020 |
| DOI | 10.1182/blood-2015-02-629204 |
Cover
| Abstract | Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non–Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% ± 2.7% and 49.0% ± 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS (P = .037) and OS (P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n = 44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): –7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1;22)(p13;q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9;11)(p22;q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk—7p abnormalities; poor risk—normal karyotypes, –7, 9p abnormalities including t(9;11)(p22;q23)/MLL-MLLT3, –13/13q-, and –15; and intermediate risk—others including t(1;22)(p13;q13)/OTT-MAL (RBM15-MKL1) and 11q23/MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes.
•AMKL patients in 2000 to 2009 had better survival than those in 1989 to 1999, but outcomes for patients in 2000 to 2004 and 2005 to 2009 were comparable.•Heterogeneous cytogenetic groups can be classified into good, intermediate, and poor risk on the basis of prognosis. |
|---|---|
| AbstractList | AMKL patients in 2000 to 2009 had better survival than those in 1989 to 1999, but outcomes for patients in 2000 to 2004 and 2005 to 2009 were comparable. Heterogeneous cytogenetic groups can be classified into good, intermediate, and poor risk on the basis of prognosis. Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non-Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% ± 2.7% and 49.0% ± 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS (P = .037) and OS (P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n = 44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): -7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1;22)(p13;q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9;11)(p22;q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk-7p abnormalities; poor risk-normal karyotypes, -7, 9p abnormalities including t(9;11)(p22;q23)/MLL-MLLT3, -13/13q-, and -15; and intermediate risk-others including t(1;22)(p13;q13)/OTT-MAL (RBM15-MKL1) and 11q23/MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes.Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non-Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% ± 2.7% and 49.0% ± 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS (P = .037) and OS (P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n = 44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): -7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1;22)(p13;q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9;11)(p22;q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk-7p abnormalities; poor risk-normal karyotypes, -7, 9p abnormalities including t(9;11)(p22;q23)/MLL-MLLT3, -13/13q-, and -15; and intermediate risk-others including t(1;22)(p13;q13)/OTT-MAL (RBM15-MKL1) and 11q23/MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes. AMKL patients in 2000 to 2009 had better survival than those in 1989 to 1999, but outcomes for patients in 2000 to 2004 and 2005 to 2009 were comparable. Heterogeneous cytogenetic groups can be classified into good, intermediate, and poor risk on the basis of prognosis. Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non–Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% ± 2.7% and 49.0% ± 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS ( P = .037) and OS ( P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n = 44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): –7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1;22)(p13;q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9;11)(p22;q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk—7p abnormalities; poor risk—normal karyotypes, –7, 9p abnormalities including t(9;11)(p22;q23)/ MLL-MLLT3 , –13/13q-, and –15; and intermediate risk—others including t(1;22)(p13;q13)/ OTT-MAL ( RBM15-MKL1 ) and 11q23/ MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes. Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age <= 18 years) with non-Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% +/- 2.7% and 49.0% +/- 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS (P = .037) and OS (P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n=44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): -7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1; 22)(p13; q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9; 11)(p22; q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk-7p abnormalities; poor risk-normal karyotypes, -7, 9p abnormalities including t(9;11)(p22;q23)/MLL-MLLT3, -13/13q-, and -15; and intermediate risk-others including t(1;22)(p13;q13)/OTT-MAL (RBM15-MKL1) and 11q23/MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes. Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non–Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% ± 2.7% and 49.0% ± 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS (P = .037) and OS (P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n = 44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): –7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1;22)(p13;q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9;11)(p22;q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk—7p abnormalities; poor risk—normal karyotypes, –7, 9p abnormalities including t(9;11)(p22;q23)/MLL-MLLT3, –13/13q-, and –15; and intermediate risk—others including t(1;22)(p13;q13)/OTT-MAL (RBM15-MKL1) and 11q23/MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes. •AMKL patients in 2000 to 2009 had better survival than those in 1989 to 1999, but outcomes for patients in 2000 to 2004 and 2005 to 2009 were comparable.•Heterogeneous cytogenetic groups can be classified into good, intermediate, and poor risk on the basis of prognosis. Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490 patients (age ≤18 years) with non-Down syndrome de novo AMKL diagnosed from 1989 to 2009. Patients with AMKL (median age 1.53 years) comprised 7.8% of pediatric AML. Five-year event-free (EFS) and overall survival (OS) were 43.7% ± 2.7% and 49.0% ± 2.7%, respectively. Patients diagnosed in 2000 to 2009 were treated with higher cytarabine doses and had better EFS (P = .037) and OS (P = .003) than those diagnosed in 1989 to 1999. Transplantation in first remission did not improve survival. Cytogenetic data were available for 372 (75.9%) patients: hypodiploid (n = 18, 4.8%), normal karyotype (n = 49, 13.2%), pseudodiploid (n = 119, 32.0%), 47 to 50 chromosomes (n = 142, 38.2%), and >50 chromosomes (n = 44, 11.8%). Chromosome gain occurred in 195 of 372 (52.4%) patients: +21 (n = 106, 28.5%), +19 (n = 93, 25.0%), +8 (n = 77, 20.7%). Losses occurred in 65 patients (17.5%): -7 (n = 13, 3.5%). Common structural chromosomal aberrations were t(1;22)(p13;q13) (n = 51, 13.7%) and 11q23 rearrangements (n = 38, 10.2%); t(9;11)(p22;q23) occurred in 21 patients. On the basis of frequency and prognosis, AMKL can be classified to 3 risk groups: good risk-7p abnormalities; poor risk-normal karyotypes, -7, 9p abnormalities including t(9;11)(p22;q23)/MLL-MLLT3, -13/13q-, and -15; and intermediate risk-others including t(1;22)(p13;q13)/OTT-MAL (RBM15-MKL1) and 11q23/MLL except t(9;11). Risk-based innovative therapy is needed to improve patient outcomes. |
| Author | Locatelli, Franco Creutzig, Ursula Taga, Takashi Auvrignon, Anne Reinhardt, Dirk Hasle, Henrik Forestier, Erik Lee, Vincent Shen, Shuhong Tomizawa, Daisuke Abla, Oussama Liang, Der-Cherng Chang, Tai-Tsung Yeoh, Allen E.J. Adachi, Souichi Zhou, Yinmei Fynn, Alcira Masetti, Riccardo Van Roy, Nadine De Moerloose, Barbara de Bont, Eveline Inaba, Hiroto Elitzur, Sarah Rodriguez, Laura Dworzak, Michael Zimmermann, Martin Raimondi, Susana C. Beverloo, H. Berna |
| Author_xml | – sequence: 1 givenname: Hiroto surname: Inaba fullname: Inaba, Hiroto email: hiroto.inaba@stjude.org organization: St. Jude Children's Research Hospital, Memphis, TN – sequence: 2 givenname: Yinmei surname: Zhou fullname: Zhou, Yinmei organization: St. Jude Children's Research Hospital, Memphis, TN – sequence: 3 givenname: Oussama surname: Abla fullname: Abla, Oussama organization: The Hospital for Sick Children, Toronto, ON, Canada – sequence: 4 givenname: Souichi surname: Adachi fullname: Adachi, Souichi organization: Kyoto University, Kyoto, Japan – sequence: 5 givenname: Anne surname: Auvrignon fullname: Auvrignon, Anne organization: French Leucémie Aigue Myeloide Enfant, Hôpital Trousseau, Paris, France – sequence: 6 givenname: H. Berna surname: Beverloo fullname: Beverloo, H. Berna organization: Erasmus Medical Center, Rotterdam, The Netherlands – sequence: 7 givenname: Eveline surname: de Bont fullname: de Bont, Eveline organization: Dutch Childhood Oncology Group, The Hague, The Netherlands – sequence: 8 givenname: Tai-Tsung surname: Chang fullname: Chang, Tai-Tsung organization: Kaohsiung Medical University Hospital, Kaohsiung, Taiwan – sequence: 9 givenname: Ursula surname: Creutzig fullname: Creutzig, Ursula organization: Medical School Hannover, Hannover, Germany – sequence: 10 givenname: Michael surname: Dworzak fullname: Dworzak, Michael organization: St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria – sequence: 11 givenname: Sarah surname: Elitzur fullname: Elitzur, Sarah organization: Schneider Children's Medical Center of Israel, Petah-Tikva, Israel – sequence: 12 givenname: Alcira surname: Fynn fullname: Fynn, Alcira organization: Children's Hospital La Plata, La Plata, Buenos Aires, Argentina – sequence: 13 givenname: Erik surname: Forestier fullname: Forestier, Erik organization: Umeå University Hospital, Umea, Sweden – sequence: 14 givenname: Henrik surname: Hasle fullname: Hasle, Henrik organization: Nordic Society for Pediatric Hematology and Oncology, Stockholm, Sweden – sequence: 15 givenname: Der-Cherng surname: Liang fullname: Liang, Der-Cherng organization: Taiwan Pediatric Oncology Group, Taipei, Taiwan – sequence: 16 givenname: Vincent surname: Lee fullname: Lee, Vincent organization: Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China – sequence: 17 givenname: Franco surname: Locatelli fullname: Locatelli, Franco organization: Istituto di Ricovero e Cura a Carattere Scientifico, Bambino Gesù Children's Hospital Rome, University of Pavia, Rome, Italy – sequence: 18 givenname: Riccardo surname: Masetti fullname: Masetti, Riccardo organization: Associazione Italiana Ematologia Oncologia Pediatrica, Bologna, Italy – sequence: 19 givenname: Barbara surname: De Moerloose fullname: De Moerloose, Barbara organization: Ghent University Hospital, Gent, Belgium – sequence: 20 givenname: Dirk surname: Reinhardt fullname: Reinhardt, Dirk organization: Acute Myeloid Leukemia-Berlin-Frankfurt-Munster Study Group, Essen, Germany – sequence: 21 givenname: Laura surname: Rodriguez fullname: Rodriguez, Laura organization: The Hospital for Sick Children, Toronto, ON, Canada – sequence: 22 givenname: Nadine surname: Van Roy fullname: Van Roy, Nadine organization: Ghent University Hospital, Gent, Belgium – sequence: 23 givenname: Shuhong surname: Shen fullname: Shen, Shuhong organization: Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 24 givenname: Takashi surname: Taga fullname: Taga, Takashi organization: Japanese Pediatric Leukemia/Lymphoma Study Group, Nagoya, Japan – sequence: 25 givenname: Daisuke surname: Tomizawa fullname: Tomizawa, Daisuke organization: Japanese Pediatric Leukemia/Lymphoma Study Group, Nagoya, Japan – sequence: 26 givenname: Allen E.J. surname: Yeoh fullname: Yeoh, Allen E.J. organization: National University Cancer Institute, National University Health System, Singapore, Singapore – sequence: 27 givenname: Martin surname: Zimmermann fullname: Zimmermann, Martin organization: Medical School Hannover, Hannover, Germany – sequence: 28 givenname: Susana C. surname: Raimondi fullname: Raimondi, Susana C. organization: St. Jude Children's Research Hospital, Memphis, TN |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26215111$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-111499$$DView record from Swedish Publication Index |
| BookMark | eNqFUstu1DAUtVARnRb-ACEv2QT8SjLpAqkqlCJVYgNsLce-yZg68eDHoNny5fU8qCgLWNmSz-P63HOGTmY_A0IvKXlD6ZK97Z33pmKE1hVhVcM6RsQTtKA1W1aEMHKCFoSQphJdS0_RWYzfCaGCs_oZOmUNozWldIF-3UCC4EeYweeI9Tbt78lqHHM_Bp_XEavZYJ-T9hNEbGesV9aZVbHHSucEeIJR3amw9b1TcUd1kO9gsuoCKxwgBR_XoJPdQGEXu1kl62flcEzZbJ-jp4NyEV4cz3P09frDl6ub6vbzx09Xl7eVrps2VbXmrCFgasUHOijVN4K1hFLeNYMxVKtWU04YUwRECwyIIqbmvBuEGBQ0mp-j6qAbf8I693Id7FSGll5Z-d5-u5Q-jDJPWZZgRNcV_LsDvoAnMBrmFJR7RHv8MtuVHP1GinrJOBdF4PVRIPgfGWKSk40anFP7sCVtadPx8gtWoK_-9How-b2oAhAHgC5hxgDDA4QSueuD3PdB7vogCZOHPhTaxV80bdM-_TKxdf8jHwOAspWNhSCjtjBrMDaUdUrj7b8F7gEeu9bA |
| CitedBy_id | crossref_primary_10_1007_s00428_024_03766_z crossref_primary_10_1007_s10555_020_09846_1 crossref_primary_10_1111_bjh_18691 crossref_primary_10_18632_oncotarget_11765 crossref_primary_10_1080_23809000_2016_1214058 crossref_primary_10_1002_pbc_29495 crossref_primary_10_1016_j_clml_2018_12_011 crossref_primary_10_3390_ijms23041968 crossref_primary_10_1007_s40272_016_0200_6 crossref_primary_10_1007_s00277_021_04488_x crossref_primary_10_1182_blood_2016_09_687889 crossref_primary_10_1097_MPH_0000000000002822 crossref_primary_10_3390_cancers13040777 crossref_primary_10_1080_17474086_2019_1609351 crossref_primary_10_1182_blood_2016_01_695551 crossref_primary_10_2217_fon_2020_0505 crossref_primary_10_1080_16078454_2023_2231731 crossref_primary_10_1159_000531480 crossref_primary_10_12659_AJCR_901855 crossref_primary_10_1016_j_clml_2020_11_001 crossref_primary_10_24953_turkjpediatr_2024_4699 crossref_primary_10_1002_pbc_28111 crossref_primary_10_35754_0234_5730_2024_69_1_104_111 crossref_primary_10_4103_2454_6798_209322 crossref_primary_10_1038_ng_3772 crossref_primary_10_1101_mcs_a005975 crossref_primary_10_1182_blood_2016_05_715045 crossref_primary_10_1111_ejh_13172 crossref_primary_10_1097_MPH_0000000000001986 crossref_primary_10_1111_bjh_15725 crossref_primary_10_1002_pbc_31267 crossref_primary_10_1002_gcc_22444 crossref_primary_10_2139_ssrn_3909747 crossref_primary_10_3390_genes12060924 crossref_primary_10_1177_2333794X16689011 crossref_primary_10_1002_pbc_28542 crossref_primary_10_1016_j_critrevonc_2019_04_011 crossref_primary_10_1111_petr_12739 crossref_primary_10_1016_j_phoj_2017_01_001 crossref_primary_10_1016_j_phoj_2021_01_001 crossref_primary_10_3389_fcell_2023_1170622 crossref_primary_10_1016_j_retram_2023_103421 crossref_primary_10_3389_fonc_2024_1441318 crossref_primary_10_1080_10428194_2018_1516883 crossref_primary_10_1016_j_jtct_2022_06_005 crossref_primary_10_1038_s41419_022_05315_5 crossref_primary_10_1080_10428194_2023_2243532 crossref_primary_10_4103_1110_1067_186415 crossref_primary_10_1016_j_celrep_2023_113084 crossref_primary_10_3389_fonc_2023_1116205 crossref_primary_10_1016_j_canep_2020_101697 crossref_primary_10_3892_mco_2023_2614 crossref_primary_10_1007_s12185_022_03504_8 crossref_primary_10_3389_fonc_2022_940725 crossref_primary_10_3390_cancers16050997 |
| Cites_doi | 10.1080/1042819021000040279 10.1016/S1470-2045(10)70090-5 10.1002/gcc.1192 10.1007/s00277-015-2383-2 10.1182/blood-2004-03-1103 10.1038/leu.2013.198 10.1182/blood.V80.9.2210.2210 10.1038/ng.2759 10.1182/blood-2002-12-3627 10.1182/blood-2009-03-209262 10.1038/leu.2012.223 10.1200/JCO.2010.32.3634 10.1111/bjh.12040 10.1182/blood.V84.1.256.256 10.1182/blood-2009-11-254441 10.1016/j.cell.2012.06.032 10.1182/blood-2001-12-0241 10.1182/blood-2013-02-484097 10.1038/sj.leu.2403815 10.1200/JCO.2008.18.7948 10.1002/pbc.20951 10.1182/blood-2009-04-215152 10.1182/blood-2013-03-491621 10.1002/gcc.22177 10.1046/j.1365-2141.1997.1722990.x 10.1200/JCO.2004.01.191 10.1182/blood-2006-10-051342 10.1200/JCO.2009.24.8997 10.1182/blood.V97.12.3727 10.1111/j.1365-2141.2007.06971.x 10.1016/j.ccr.2012.10.007 10.1111/bjh.13096 10.1084/jem.20121343 10.1038/leu.2013.87 10.1200/JCO.2008.16.0259 10.1080/01621459.1958.10501452 |
| ContentType | Journal Article |
| Copyright | 2015 American Society of Hematology 2015 by The American Society of Hematology. 2015 by The American Society of Hematology 2015 |
| Copyright_xml | – notice: 2015 American Society of Hematology – notice: 2015 by The American Society of Hematology. – notice: 2015 by The American Society of Hematology 2015 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTPV AOWAS D93 |
| DOI | 10.1182/blood-2015-02-629204 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Umeå universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| EndPage | 1584 |
| ExternalDocumentID | oai_DiVA_org_umu_111499 PMC4582334 26215111 10_1182_blood_2015_02_629204 S0006497120308909 |
| Genre | Clinical Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA021765 – fundername: National Institutes of Health |
| GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ AALRI AAYXX ACVFH ADCNI ADVLN AEUPX AFPUW AGCQF AIGII AITUG AKBMS AKRWK AKYEP AMRAJ CITATION H13 CGR CUY CVF ECM EIF NPM 7X8 EFKBS 5PM .GJ 9M8 AAQQT AAYWO ADTPV AFFNX AI. AOWAS C1A D93 J5H MVM N4W OHT VH1 WHG ZGI ZXP |
| ID | FETCH-LOGICAL-c567t-5c3260ed5a3f1faab6427011396fdd1ca7c13022a0e47e2e0a0d5339f44fae6c3 |
| ISSN | 0006-4971 1528-0020 |
| IngestDate | Thu Aug 21 06:46:32 EDT 2025 Thu Aug 21 18:25:33 EDT 2025 Fri Sep 05 08:54:34 EDT 2025 Wed Feb 19 02:30:34 EST 2025 Tue Jul 01 02:15:38 EDT 2025 Thu Apr 24 23:04:01 EDT 2025 Fri Feb 23 02:44:40 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Language | English |
| License | This article is made available under the Elsevier license. 2015 by The American Society of Hematology. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c567t-5c3260ed5a3f1faab6427011396fdd1ca7c13022a0e47e2e0a0d5339f44fae6c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2015-02-629204 |
| PMID | 26215111 |
| PQID | 1716934272 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | swepub_primary_oai_DiVA_org_umu_111499 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4582334 proquest_miscellaneous_1716934272 pubmed_primary_26215111 crossref_primary_10_1182_blood_2015_02_629204 crossref_citationtrail_10_1182_blood_2015_02_629204 elsevier_sciencedirect_doi_10_1182_blood_2015_02_629204 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-09-24 |
| PublicationDateYYYYMMDD | 2015-09-24 |
| PublicationDate_xml | – month: 09 year: 2015 text: 2015-09-24 day: 24 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington, DC |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2015 |
| Publisher | Elsevier Inc American Society of Hematology |
| Publisher_xml | – name: Elsevier Inc – name: American Society of Hematology |
| References | Roberts, Izraeli (bib7) 2014; 167 Tsukimoto, Tawa, Horibe (bib20) 2009; 27 Harrison, Hills, Moorman (bib25) 2010; 28 Hasle, Alonzo, Auvrignon (bib18) 2007; 109 Alvarez, MacGrogan, Calasanz, Nimer, Jhanwar (bib31) 2001; 32 Garderet, Labopin, Gorin (bib10) 2005; 105 Schweitzer, Zimmermann, Rasche (bib9) 2015; 94 Breems, Van Putten, De Greef (bib33) 2008; 26 Kaplan, Meier (bib14) 1958; 53 Mantel, Haenszel (bib15) 1959; 22 Vardiman, Thiele, Arber (bib6) 2009; 114 Balgobind, Raimondi, Harbott (bib24) 2009; 114 Barnard, Alonzo, Gerbing, Lange, Woods (bib8) 2007; 49 Inaba, Londero, Maurer (bib16) 2011; 29 Reilly, Snowden, Spearing (bib32) 1997; 98 Kornblau, Xu, Zhang (bib30) 1994; 84 Wen, Goldenson, Silver (bib23) 2012; 150 Dastugue, Lafage-Pochitaloff, Pagès (bib4) 2002; 100 Grimwade, Hills, Moorman (bib34) 2010; 116 Chilton, Hills, Harrison, Burnett, Grimwade, Moorman (bib17) 2014; 28 Pession, Masetti, Rizzari (bib21) 2013; 122 Duchayne, Fenneteau, Pages (bib35) 2003; 44 Hama, Yagasaki, Takahashi (bib2) 2008; 140 Gruber, Larson Gedman, Zhang (bib27) 2012; 22 Sandahl, Kjeldsen, Abrahamsson (bib5) 2014; 53 Ravindranath, Abella, Krischer (bib37) 1992; 80 O’Brien, Cao, Pounds (bib12) 2013; 27 ISCN. In: Shaffer LG, Slovak ML, Campbell LJ, eds. An International System for Human Cytogenetics Nomenclature. Basel: S. Karger; 2009. Creutzig, Zimmermann, Bourquin (bib22) 2013; 122 Yoshida, Toki, Okuno (bib38) 2013; 45 Rubnitz, Inaba (bib19) 2012; 159 de Rooij, Hollink, Arentsen-Peters (bib28) 2013; 27 Rubnitz, Inaba, Dahl (bib11) 2010; 11 Thiollier, Lopez, Gerby (bib29) 2012; 209 Reinhardt, Diekamp, Langebrake (bib3) 2005; 19 Creutzig, Zimmermann, Reinhardt, Dworzak, Stary, Lehrnbecher (bib36) 2004; 22 Athale, Razzouk, Raimondi (bib1) 2001; 97 Zwaan, Meshinchi, Radich (bib26) 2003; 102 Thiollier (2019111815044288900_B29) 2012; 209 Grimwade (2019111815044288900_B34) 2010; 116 Garderet (2019111815044288900_B10) 2005; 105 Alvarez (2019111815044288900_B31) 2001; 32 Gruber (2019111815044288900_B27) 2012; 22 Creutzig (2019111815044288900_B22) 2013; 122 Duchayne (2019111815044288900_B35) 2003; 44 Breems (2019111815044288900_B33) 2008; 26 Wen (2019111815044288900_B23) 2012; 150 Hama (2019111815044288900_B2) 2008; 140 Barnard (2019111815044288900_B8) 2007; 49 Roberts (2019111815044288900_B7) 2014; 167 Balgobind (2019111815044288900_B24) 2009; 114 Hasle (2019111815044288900_B18) 2007; 109 Ravindranath (2019111815044288900_B37) 1992; 80 Rubnitz (2019111815044288900_B11) 2010; 11 Mantel (2019111815044288900_B15) 1959; 22 Sandahl (2019111815044288900_B5) 2014; 53 Kaplan (2019111815044288900_B14) 1958; 53 O’Brien (2019111815044288900_B12) 2013; 27 Reinhardt (2019111815044288900_B3) 2005; 19 Pession (2019111815044288900_B21) 2013; 122 de Rooij (2019111815044288900_B28) 2013; 27 Vardiman (2019111815044288900_B6) 2009; 114 Zwaan (2019111815044288900_B26) 2003; 102 Yoshida (2019111815044288900_B38) 2013; 45 Athale (2019111815044288900_B1) 2001; 97 Rubnitz (2019111815044288900_B19) 2012; 159 Reilly (2019111815044288900_B32) 1997; 98 Tsukimoto (2019111815044288900_B20) 2009; 27 Schweitzer (2019111815044288900_B9) 2015; 94 2019111815044288900_B13 Chilton (2019111815044288900_B17) 2014; 28 Inaba (2019111815044288900_B16) 2011; 29 Dastugue (2019111815044288900_B4) 2002; 100 Harrison (2019111815044288900_B25) 2010; 28 Creutzig (2019111815044288900_B36) 2004; 22 Kornblau (2019111815044288900_B30) 1994; 84 |
| References_xml | – volume: 114 start-page: 2489 year: 2009 end-page: 2496 ident: bib24 article-title: Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study publication-title: Blood – volume: 94 start-page: 1327 year: 2015 end-page: 1336 ident: bib9 article-title: Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial publication-title: Ann Hematol – volume: 97 start-page: 3727 year: 2001 end-page: 3732 ident: bib1 article-title: Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience publication-title: Blood – volume: 19 start-page: 1495 year: 2005 end-page: 1496 ident: bib3 article-title: Acute megakaryoblastic leukemia in children and adolescents, excluding Down’s syndrome: improved outcome with intensified induction treatment publication-title: Leukemia – volume: 167 start-page: 587 year: 2014 end-page: 599 ident: bib7 article-title: Haematopoietic development and leukaemia in Down syndrome publication-title: Br J Haematol – volume: 49 start-page: 17 year: 2007 end-page: 22 ident: bib8 article-title: Children’s Oncology Group publication-title: Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.,Pediatr Blood Cancer – volume: 102 start-page: 2387 year: 2003 end-page: 2394 ident: bib26 article-title: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance publication-title: Blood – volume: 29 start-page: e230 year: 2011 end-page: e233 ident: bib16 article-title: Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome publication-title: J Clin Oncol – volume: 159 start-page: 259 year: 2012 end-page: 276 ident: bib19 article-title: Childhood acute myeloid leukaemia publication-title: Br J Haematol – volume: 80 start-page: 2210 year: 1992 end-page: 2214 ident: bib37 article-title: Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 publication-title: Blood – volume: 114 start-page: 937 year: 2009 end-page: 951 ident: bib6 article-title: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes publication-title: Blood – volume: 98 start-page: 96 year: 1997 end-page: 102 ident: bib32 article-title: Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases publication-title: Br J Haematol – volume: 44 start-page: 49 year: 2003 end-page: 58 ident: bib35 article-title: Groupe Français d'Hématologie Cellulaire; Groupe Français de Cytogénétique Hématologique publication-title: Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Français d'Hématologie Cellulaire (GFHC).,Leuk Lymphoma – volume: 105 start-page: 405 year: 2005 end-page: 409 ident: bib10 article-title: Acute Leukemia Working Party and Pediatric Working Party of the European Group for Blood and Marrow Transplantation publication-title: Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).,Blood – volume: 27 start-page: 4007 year: 2009 end-page: 4013 ident: bib20 article-title: Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group publication-title: J Clin Oncol – volume: 100 start-page: 618 year: 2002 end-page: 626 ident: bib4 article-title: Groupe Français d'Hematologie Cellulaire publication-title: Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de’Cytogénétique Hématologique (GFCH).,Blood – volume: 22 start-page: 719 year: 1959 end-page: 748 ident: bib15 article-title: Statistical aspects of the analysis of data from retrospective studies of disease publication-title: J Natl Cancer Inst – volume: 53 start-page: 667 year: 2014 end-page: 675 ident: bib5 article-title: Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study publication-title: Genes Chromosomes Cancer – volume: 26 start-page: 4791 year: 2008 end-page: 4797 ident: bib33 article-title: Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype publication-title: J Clin Oncol – volume: 27 start-page: 731 year: 2013 end-page: 734 ident: bib12 article-title: Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421 publication-title: Leukemia – volume: 116 start-page: 354 year: 2010 end-page: 365 ident: bib34 article-title: National Cancer Research Institute Adult Leukaemia Working Group publication-title: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.,Blood – volume: 45 start-page: 1293 year: 2013 end-page: 1299 ident: bib38 article-title: The landscape of somatic mutations in Down syndrome-related myeloid disorders publication-title: Nat Genet – volume: 122 start-page: 170 year: 2013 end-page: 178 ident: bib21 article-title: AIEOP AML Study Group publication-title: Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia.,Blood – volume: 53 start-page: 457 year: 1958 end-page: 481 ident: bib14 article-title: Nonparametric estimation from incomplete observations publication-title: J Am Stat Assoc – volume: 150 start-page: 575 year: 2012 end-page: 589 ident: bib23 article-title: Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL publication-title: Cell – reference: ISCN. In: Shaffer LG, Slovak ML, Campbell LJ, eds. An International System for Human Cytogenetics Nomenclature. Basel: S. Karger; 2009. – volume: 109 start-page: 4641 year: 2007 end-page: 4647 ident: bib18 article-title: Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study publication-title: Blood – volume: 22 start-page: 683 year: 2012 end-page: 697 ident: bib27 article-title: An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia publication-title: Cancer Cell – volume: 27 start-page: 2280 year: 2013 end-page: 2288 ident: bib28 article-title: NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern publication-title: Leukemia – volume: 32 start-page: 285 year: 2001 end-page: 293 ident: bib31 article-title: Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization publication-title: Genes Chromosomes Cancer – volume: 28 start-page: 2674 year: 2010 end-page: 2681 ident: bib25 article-title: Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12 publication-title: J Clin Oncol – volume: 22 start-page: 4384 year: 2004 end-page: 4393 ident: bib36 article-title: Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98 publication-title: J Clin Oncol – volume: 140 start-page: 552 year: 2008 end-page: 561 ident: bib2 article-title: Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome publication-title: Br J Haematol – volume: 11 start-page: 543 year: 2010 end-page: 552 ident: bib11 article-title: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial publication-title: Lancet Oncol – volume: 122 start-page: 37 year: 2013 end-page: 43 ident: bib22 article-title: Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004 publication-title: Blood – volume: 84 start-page: 256 year: 1994 end-page: 261 ident: bib30 article-title: Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia publication-title: Blood – volume: 209 start-page: 2017 year: 2012 end-page: 2031 ident: bib29 article-title: Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models publication-title: J Exp Med – volume: 28 start-page: 321 year: 2014 end-page: 328 ident: bib17 article-title: Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome publication-title: Leukemia – volume: 44 start-page: 49 issue: 1 year: 2003 ident: 2019111815044288900_B35 article-title: Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Français d’Hématologie Cellulaire (GFHC). publication-title: Leuk Lymphoma doi: 10.1080/1042819021000040279 – volume: 11 start-page: 543 issue: 6 year: 2010 ident: 2019111815044288900_B11 article-title: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70090-5 – volume: 32 start-page: 285 issue: 3 year: 2001 ident: 2019111815044288900_B31 article-title: Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization. publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.1192 – volume: 94 start-page: 1327 issue: 8 year: 2015 ident: 2019111815044288900_B9 article-title: Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. publication-title: Ann Hematol doi: 10.1007/s00277-015-2383-2 – volume: 105 start-page: 405 issue: 1 year: 2005 ident: 2019111815044288900_B10 article-title: Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). publication-title: Blood doi: 10.1182/blood-2004-03-1103 – volume: 28 start-page: 321 issue: 2 year: 2014 ident: 2019111815044288900_B17 article-title: Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. publication-title: Leukemia doi: 10.1038/leu.2013.198 – volume: 80 start-page: 2210 issue: 9 year: 1992 ident: 2019111815044288900_B37 article-title: Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. publication-title: Blood doi: 10.1182/blood.V80.9.2210.2210 – volume: 45 start-page: 1293 issue: 11 year: 2013 ident: 2019111815044288900_B38 article-title: The landscape of somatic mutations in Down syndrome-related myeloid disorders. publication-title: Nat Genet doi: 10.1038/ng.2759 – volume: 102 start-page: 2387 issue: 7 year: 2003 ident: 2019111815044288900_B26 article-title: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. publication-title: Blood doi: 10.1182/blood-2002-12-3627 – volume: 114 start-page: 937 issue: 5 year: 2009 ident: 2019111815044288900_B6 article-title: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. publication-title: Blood doi: 10.1182/blood-2009-03-209262 – volume: 27 start-page: 731 issue: 3 year: 2013 ident: 2019111815044288900_B12 article-title: Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421. publication-title: Leukemia doi: 10.1038/leu.2012.223 – volume: 29 start-page: e230 issue: 9 year: 2011 ident: 2019111815044288900_B16 article-title: Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome. publication-title: J Clin Oncol doi: 10.1200/JCO.2010.32.3634 – volume: 159 start-page: 259 issue: 3 year: 2012 ident: 2019111815044288900_B19 article-title: Childhood acute myeloid leukaemia. publication-title: Br J Haematol doi: 10.1111/bjh.12040 – volume: 84 start-page: 256 issue: 1 year: 1994 ident: 2019111815044288900_B30 article-title: Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. publication-title: Blood doi: 10.1182/blood.V84.1.256.256 – volume: 22 start-page: 719 issue: 4 year: 1959 ident: 2019111815044288900_B15 article-title: Statistical aspects of the analysis of data from retrospective studies of disease. publication-title: J Natl Cancer Inst – volume: 116 start-page: 354 issue: 3 year: 2010 ident: 2019111815044288900_B34 article-title: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. publication-title: Blood doi: 10.1182/blood-2009-11-254441 – volume: 150 start-page: 575 issue: 3 year: 2012 ident: 2019111815044288900_B23 article-title: Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. publication-title: Cell doi: 10.1016/j.cell.2012.06.032 – volume: 100 start-page: 618 issue: 2 year: 2002 ident: 2019111815044288900_B4 article-title: Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH). publication-title: Blood doi: 10.1182/blood-2001-12-0241 – volume: 122 start-page: 37 issue: 1 year: 2013 ident: 2019111815044288900_B22 article-title: Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. publication-title: Blood doi: 10.1182/blood-2013-02-484097 – volume: 19 start-page: 1495 issue: 8 year: 2005 ident: 2019111815044288900_B3 article-title: Acute megakaryoblastic leukemia in children and adolescents, excluding Down’s syndrome: improved outcome with intensified induction treatment. publication-title: Leukemia doi: 10.1038/sj.leu.2403815 – volume: 27 start-page: 4007 issue: 24 year: 2009 ident: 2019111815044288900_B20 article-title: Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.7948 – volume: 49 start-page: 17 issue: 1 year: 2007 ident: 2019111815044288900_B8 article-title: Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children’s Oncology Group. publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.20951 – volume: 114 start-page: 2489 issue: 12 year: 2009 ident: 2019111815044288900_B24 article-title: Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. publication-title: Blood doi: 10.1182/blood-2009-04-215152 – volume: 122 start-page: 170 issue: 2 year: 2013 ident: 2019111815044288900_B21 article-title: Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. publication-title: Blood doi: 10.1182/blood-2013-03-491621 – volume: 53 start-page: 667 issue: 8 year: 2014 ident: 2019111815044288900_B5 article-title: Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study. publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.22177 – volume: 98 start-page: 96 issue: 1 year: 1997 ident: 2019111815044288900_B32 article-title: Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. publication-title: Br J Haematol doi: 10.1046/j.1365-2141.1997.1722990.x – volume: 22 start-page: 4384 issue: 21 year: 2004 ident: 2019111815044288900_B36 article-title: Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. publication-title: J Clin Oncol doi: 10.1200/JCO.2004.01.191 – volume: 109 start-page: 4641 issue: 11 year: 2007 ident: 2019111815044288900_B18 article-title: Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. publication-title: Blood doi: 10.1182/blood-2006-10-051342 – volume: 28 start-page: 2674 issue: 16 year: 2010 ident: 2019111815044288900_B25 article-title: Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.8997 – volume: 97 start-page: 3727 issue: 12 year: 2001 ident: 2019111815044288900_B1 article-title: Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience. publication-title: Blood doi: 10.1182/blood.V97.12.3727 – volume: 140 start-page: 552 issue: 5 year: 2008 ident: 2019111815044288900_B2 article-title: Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2007.06971.x – volume: 22 start-page: 683 issue: 5 year: 2012 ident: 2019111815044288900_B27 article-title: An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.10.007 – ident: 2019111815044288900_B13 – volume: 167 start-page: 587 issue: 5 year: 2014 ident: 2019111815044288900_B7 article-title: Haematopoietic development and leukaemia in Down syndrome. publication-title: Br J Haematol doi: 10.1111/bjh.13096 – volume: 209 start-page: 2017 issue: 11 year: 2012 ident: 2019111815044288900_B29 article-title: Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. publication-title: J Exp Med doi: 10.1084/jem.20121343 – volume: 27 start-page: 2280 issue: 12 year: 2013 ident: 2019111815044288900_B28 article-title: NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. publication-title: Leukemia doi: 10.1038/leu.2013.87 – volume: 26 start-page: 4791 issue: 29 year: 2008 ident: 2019111815044288900_B33 article-title: Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.0259 – volume: 53 start-page: 457 issue: 282 year: 1958 ident: 2019111815044288900_B14 article-title: Nonparametric estimation from incomplete observations. publication-title: J Am Stat Assoc doi: 10.1080/01621459.1958.10501452 |
| SSID | ssj0014325 |
| Score | 2.4418616 |
| Snippet | Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL) are lacking. We performed an international retrospective study on 490... AMKL patients in 2000 to 2009 had better survival than those in 1989 to 1999, but outcomes for patients in 2000 to 2004 and 2005 to 2009 were comparable.... |
| SourceID | swepub pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1575 |
| SubjectTerms | Adolescent Antimetabolites, Antineoplastic - therapeutic use Child Child, Preschool Chromosome Aberrations Cytarabine - therapeutic use Disease-Free Survival Female Gene Rearrangement Hematopoietic Stem Cell Transplantation Humans Infant Kaplan-Meier Estimate Karyotyping Leukemia, Megakaryoblastic, Acute - diagnosis Leukemia, Megakaryoblastic, Acute - epidemiology Leukemia, Megakaryoblastic, Acute - genetics Leukemia, Megakaryoblastic, Acute - therapy Male Myeloid Neoplasia Prognosis Retrospective Studies Treatment Outcome |
| Title | Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study |
| URI | https://dx.doi.org/10.1182/blood-2015-02-629204 https://www.ncbi.nlm.nih.gov/pubmed/26215111 https://www.proquest.com/docview/1716934272 https://pubmed.ncbi.nlm.nih.gov/PMC4582334 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-111499 |
| Volume | 126 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEJcXBBuXcpOR0N4CrnNxylsZoAo0ENKG9mY5iTOitfGUJg9FPPHLObbjpKGbBrxEVmL3VPm-HB_7XIzQywzusiijXsIY8YI0I55Iw8ALYO7JRcZIkuj9jsPP0fw4-HgSnoxGPzezS-rkVfrjwryS_0EV7gGuOkv2H5DtfhRuQBvwhSsgDNe_wniuY1kUPJY6kDVd16atS7CumsTka9gKzKqpQbwJvbLZ26aWsUh1jMBSnoozUa1VAna0HrqQzZlcFsKmQVeyrpRLxzTFJfr9w740rfMKL9qj5w3ZSpEYy3ReVKpW_Q61aoze13EIRe99Wpi-X5rVSvRTxSzTsZ5mh1Y1BTQ3NykmoWf8NnaOaRWrroRNKBloXpss7yjmbyjSSWgPVNnW8LGuGGuj-q0k6kX6yK1gszu8ovOlQZ1G2qhpFfqwsrZ7dA1dp4xNdEDop6-9DyrwadgmW4LQ1xeJ1KWk2x-5zK7ZXrdsh98OitQaw-boLrrTrkjwzNLrHhrJchftzQBltVzjfWxihI3zZRfdeOtatw7cSYG76OZhG6Cxh34NKIk3KIk7SmKgJHaUxEWJO0piQ0n8JyWxo-QbLPCAkHhASGwIeR8df3h_dDD32mM-vDSMWO2FKSwhiMxC4eegH0QCS2IG044_jfIsm4AuSbV3nQoiAyapJIJksEiZ5kGQCxml_gO0U6pSPkIY7Nk8jOI802lPAEwSEyYnUxEzSnIWx2PkO5B42tbA10exLLhZC8eUG5S5RpkTyi3KY-R1o85tDZgr-jOHP2_tWGufciDxFSNfOLpwwFD77oTBi5uqVj68GDpGDy19uv_iKAhyB8TqOugS8sMnZfHdlJLXXnPfB7n7loKDIe-KbzOuqlPeLBu9UxBMp48vFf4E3e4__Kdop64a-Qzs9Tp5bj6r3wpr8Ow |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heterogeneous+cytogenetic+subgroups+and+outcomes+in+childhood+acute+megakaryoblastic+leukemia%3A+a+retrospective+international+study&rft.jtitle=Blood&rft.au=Inaba%2C+Hiroto&rft.au=Zhou%2C+Yinmei&rft.au=Abla%2C+Oussama&rft.au=Adachi%2C+Souichi&rft.date=2015-09-24&rft.eissn=1528-0020&rft.volume=126&rft.issue=13&rft.spage=1575&rft_id=info:doi/10.1182%2Fblood-2015-02-629204&rft_id=info%3Apmid%2F26215111&rft.externalDocID=26215111 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |